Furthermore, this progress may be more attributable to oral medications than to new insulin form because, the use of the new insulin such as glargine was stable and the use of detemir doubled but remained low (16%) during our study period[19], despite that studies showed that glargine and detemir cause less hypoglycemia compared to neutral protamine Hagedorn inslulin [20–22]. This evidence concerns the gene INS and Hypoglycemia.